Impact factor (WEB OF SCIENCE - Clarivate)

2 year: 7.2 | 5 year: 6.6

Articles | COVID-19

A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries

Stephanie Chow Garbern1, Pryanka Relan2, Gerard M O’Reilly3,4, Corey B Bills5, Megan Schultz6(), Indi Trehan7, Sean M Kivlehan8,9, Torben K Becker10

1 Department of Emergency Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
2 Department of Emergency Medicine, Emory Healthcare Network, Atlanta, Georgia, USA
3 Emergency and Trauma Centre, The Alfred, Melbourne, Australia
4 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
5 Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA
6 Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
7 Departments of Pediatrics, Global Health, and Epidemiology, University of Washington, Seattle, Washington, USA
8 Department of Emergency Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
9 Harvard Humanitarian Initiative, Cambridge, Massachusetts, USA
10 Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA

DOI: 10.7189/jogh.12.05039




Severe acute respiratory infections (SARIs) remain a leading cause of death globally, particularly in low- and middle-income countries (LMICs). Early intervention is critical, considering the potential for rapid decompensation in patients with SARIs. We aimed to evaluate the impact of acute and emergency care interventions on improving clinical outcomes in patients >10 years old with SARIs in LMICs.


A systematic literature search was performed in PubMed, Global Health, and Global Index Medicus databases to identify peer-reviewed studies containing SARI, LMICs, and emergency care interventions. Studies published prior to November 2020 focusing on patients >10 years old were included. A narrative synthesis was performed due to the heterogeneity of identified articles. Risk of bias was assessed using the Risk of Bias 2 and Risk of Bias In Non-Randomized Studies of Interventions tools.


20 223 studies were screened and 58 met the inclusion criteria. Thirty-four studies focused on coronavirus-2019 (COVID-19), 15 on pneumonia, seven on influenza, one study on severe acute respiratory syndrome, and one on undifferentiated SARI. Few COVID-19 studies found a benefit of the tested intervention on clinical status, mortality, or hospital length-of-stay. Little to no benefit was found for azithromycin, convalescent plasma, or zinc, and potential harm was found for hydroxychloroquine/chloroquine. There was mixed evidence for immunomodulators, traditional Chinese medicine, and corticosteroids among COVID-19 studies, with notable confounding due to a lack of consistency of control group treatments. Neuraminidase inhibitor antivirals for influenza had the highest quality of evidence for shortening symptom duration and decreasing disease severity.


We found few interventions for SARIs in LMICs with have high-quality evidence for improving clinical outcomes. None of the included studies evaluated non-pharmacologic interventions or were conducted in low-income countries. Further studies evaluating the impact of antivirals, immunomodulators, corticosteroids, and non-pharmacologic interventions for SARIs in LMICs are urgently needed.


PROSPERO registration number: CRD42020216117

Print Friendly, PDF & Email

Severe acute respiratory infections (SARI), including those resulting in pneumonia, cause an estimated four million deaths annually and are the leading communicable cause of death worldwide [1]. While SARIs affect all age groups, the highest mortality is seen in the youngest and oldest age groups, with 45% of all global deaths from lower respiratory infections occurring in those over 70 years old [24]. Furthermore, adult and pediatric populations with SARIs have been shown to have substantial differences in epidemiology, clinical presentation, management, and mortality risk [2]. Among adults, older age has been most strongly associated with an increased risk of hospitalization and death from SARIs [3,4].

The 2011 World Health Organization (WHO) case definition of SARI as “an acute respiratory infection with cough and fever which requires hospitalization” was created in response to the 2009-2010 H1N1 influenza pandemic and has since played an important role in public health surveillance and preparedness for monitoring influenza and novel respiratory pathogens [5,6]. While SARIs are a major cause of global morbidity and mortality worldwide, they particularly affect low- and middle-income countries (LMICs) with limited health care resources, especially during outbreaks [7]. SARIs encompass acute respiratory infections regardless of cause, including influenza, respiratory syncytial viruses, coronaviruses, and bacterial and fungal pathogens [5,8]. Certain viral aetiologies of SARI pose a danger of becoming pandemics, such as pandemic influenza A (H1N1/09), Middle East respiratory syndrome coronavirus (MERS-CoV) and most recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [9].

The SARI case definition was intentionally developed to be easily applicable and have high sensitivity to capture the burden of influenza and novel respiratory pathogens across a wide variety of settings [5,8]. Although SARIs are a major cause of morbidity and mortality in LMICs, the aetiology of SARIs is often unconfirmed in low-resource settings due to a lack of diagnostic testing capacity [10]. Moreover, the health care resources needed to manage SARIs may be significantly limited in LMICs. Resources such as emergency and critical care support, including supplemental oxygen, antivirals, ventilators, immunomodulators and other therapeutics can impact the course of disease in patients with SARIs and prevent progression to respiratory failure, acute respiratory distress syndrome (ARDS), sepsis, or death, however the availability of these resources and their impact on clinical course are poorly characterized in LMICs [11,12].

Given the potential rapid clinical progression and high mortality rates from SARIs, acute and emergency care interventions are key in improving patient outcomes. Despite recent advances in characterizing the etiologist, incidence, and therapeutics used for SARIs, especially for the novel coronavirus disease 2019 (COVID-19), knowledge gaps persist in identifying acute and emergency care interventions most effective in improving clinical outcomes in adolescents and adults with SARIs in LMICs. Filling these gaps is critical to ensure that limited resources are optimally targeted towards feasible and effective interventions. The aim of this systematic review was to evaluate the impact of acute and emergency care interventions on improving clinical outcomes of adolescent and adults with SARIs in LMICs.


This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for systematic reviews and developed in collaboration with the Global Emergency Medicine Literature Review (GEMLR) group [13]. The review was registered on PROSPERO (registration number CRD42019151080) on October 29, 2020. The published study protocol is shown in Appendix S1 of the Online Supplementary Document. As only published, de-identified data were used, this study was exempt from institutional review board approval.

Search strategy and data sources

The initial search strategy was developed in PubMed and adapted for the Global Health and Global Index Medicus databases using a combination of controlled vocabulary and text word search terms, combining the concepts of SARI, emergency care interventions, and LMICs (Appendix S2 in Online Supplementary Document). Free text terms and standardized MeSH headings/subheadings in the context of Boolean operators and appropriate search term truncation were utilized to optimize sensitivity for relevant literature while minimizing excess search results. The search strategy was optimized via multiple trial searches, verifying that all previously identified relevant studies were included. The reference lists of similar reviews were searched manually to both verify search sensitivity and identify other potentially relevant studies. A manual grey literature search was also performed via advanced Google searches targeting organizations known to publish global emergency care literature. Searches were conducted November 2020 to January 2021 and duplicates removed prior to screening.

Inclusion criteria

Eligible studies included all randomized controlled trials (RCTs) and observational studies with a comparator group that were conducted in LMICS, included patients with SARI, studied an emergency care intervention, and investigated patient-centric clinical outcomes. These criteria are further defined as follows:

  1. The WHO SARI case definition of any acute respiratory infection with a history of fever (or measured fever of ≥ 38°C) and cough with onset within the last 10 days which requires hospitalization [5] had to be fulfilled. SARI was used as the case definition because of its global use in public health surveillance, and to capture the wide array of acute respiratory infections that may require emergency care. Studies were screened based on the SARI criteria themselves (i.e., regardless of whether the term “SARI” itself was used) due to a lack of consistent implementation of SARI surveillance across all LMIC contexts. Using a broad definition was necessary, as the aetiology of severe respiratory infections is rarely determined in LMIC emergency settings, especially during the initial treatment and stabilization of patients [10,14,15].
  2. Acute and emergency care interventions were defined as relevant interventions (determined by the co-authors’ clinical experience) initiated in the early period of care (within approximately 24 hours), recognizing that the definition of emergency care may extend beyond this period. As much emergency care in LMICs may occur outside of emergency wards or much inpatient care may be conducted in emergency wards due to overcrowding and boarding, no restrictions on setting were used (i.e., pre-hospital or ambulatory settings, inpatient, emergency, and intensive care units were included) [16,17].
  3. Only studies which evaluated patient-centric clinical outcomes were included. Primary outcomes included mortality, need for intensive care unit (ICU) admission, need for mechanical ventilation, hospital length-of-stay, clinical severity, symptom duration, symptom severity. Physiologic parameters and time to viral clearance (negative polymerase chain reaction (PCR) test) were included if relevant to patient-centric outcomes (e.g., ability to be discharged).
  4. LMICs were defined using the 2020 World Bank classification [18].

Both paediatric and adult articles were included in the initial screening process. However, given the variations in SARI epidemiology and management between adults and children, the two groups were analysed separately. The present study focused on adolescents (10-19 years) and adults (20 years of age or older) as per the WHO definitions [19]. Articles on paediatric populations will be included in future publications.

Study selection

Two reviewers independently screened each title and abstract. One author (SCG) screened all titles and abstracts and co-authors (CB, GO, PR, and MS) screened one quarter each, with discrepancies resolved by a third reviewer. The same procedure was followed for full-text screening. Articles were excluded if they were not in English or Spanish (based on language capacity of the co-authors), were irrelevant to the topic (eg, chronic disease management), evaluated non-health related outcomes (eg, economic outcomes), were not undertaken in an LMIC, or only consisted of an abstract.

Assessment of risk of bias

Two authors independently assessed the included studies for risk of bias using the Cochrane Risk of Bias 2 (RoB 2) tool for randomized trials and the Risk Of Bias in Non-Randomized Studies (ROBINS-I) tool for observational studies [20,21]. Discrepancies between reviewers were resolved by a third author.

Data extraction and analysis

Two authors independently evaluated each article and extracted data on a standardized form. A third author resolved any discrepancies. Form fields included the author, title, publication date, study country, World Bank country classification, study setting, study design, disease studied, intervention description, primary and secondary outcomes, and limitations. A qualitative analysis and narrative synthesis were undertaken because the criteria for a formal meta-analysis (study methodology, intervention, outcomes) were not met. As nearly all studies evaluated interventions for a specific condition/pathogen, the results were presented in terms of the primary condition studied, and subsequently by intervention category, using the United States Pharmacopeia therapeutic categories (eg, antibiotics, corticosteroids, immunomodulators, nutrients and minerals) [22]. Results are presented with the highest quality of evidence first (RCTs without significant risk of bias), followed by results from observational studies and RCTs with serious bias concerns.


Description of included studies

We retrieved 25 180 studies and removed 4957 duplicates. Full texts of 292 articles were screened and 58 studies included for analysis (Figure 1). Study characteristics (study country, study design, and types of intervention) are shown in Table 1. Thirty-four (59%) studies were on COVID-19, 15 (26%) on community-acquired pneumonia (CAP) or lower respiratory tract infections (LRTI), seven (12%) on influenza (including subtypes H1N1 and H7N9), one on SARS and one on SARI in general. There were 36 (64%) RCTs, 18 (31%) retrospective cohort studies, two (3%) case-control studies, one (2%) non-randomized trial, and one (2%) prospective cohort study. More than two-third of included studies (n = 40; 69%) were conducted in upper middle-income countries while 18 (31%) were in lower middle-income countries. No studies were conducted in low-income countries (LIC). The most represented regions (using WHO region definitions) were Western Pacific (n = 29; 50%), Eastern Mediterranean (n = 15; 25.9%), Americas (n = 10; 17.2%), South-East Asia (n = 3; 5.2%), and Africa (n = 1; 1.7%). Most studies were conducted in China (n = 26; 44.8%), Iran (n = 10; 17.2%), and Brazil (n = 9; 15.5%). A full listing of study countries is shown in Table 1.

Figure 1.  PRISMA flow diagram.

Table 1.  Characteristics of the included studies (n = 58)

CAP – community-acquired pneumonia, COVID-19 – coronavirus disease 2019, LRTI – lower respiratory tract infection, RCT – randomized-controlled trial, SARS – severe acute respiratory syndrome (SARS-associated coronavirus), SARI – severe acute respiratory infection, TCM – traditional Chinese medicine, N – number of participants

Risk of bias

Figure 2 and Figure 3 summarize the RoB 2 assessment for RCTs and ROBINS-I assessment for non-randomized and observational studies. Figure S1 and S2 in the Online Supplementary Document show the individual RoB 2 and ROBINS-I assessments for each study. Among RCTs, eight studies had overall low risk of bias, 23 had some concerns, and five had high risk. Among non-randomized and observational studies, two studies had low overall risk of bias, nine had moderate risk, and 11 had serious risk of bias.

Figure 2.  Summary of risk of bias assessments for included randomized-controlled trials using Cochrane’s Risk of Bias tool for randomized trials version 2 (RoB 2).

Figure 3.  Summary of risk of bias assessments for included non-randomized studies according to the ROBINS-I tool.


Of the 34 articles on COVID-19, there were 22 RCTs, one non-randomized trial, and 11 observational studies. Interventions included antibiotics, antiparasitics, antivirals, convalescent plasma, corticosteroids, immunomodulators, nutrients and minerals, respiratory tract agents, and traditional Chinese medicine (TCM) (Table 2). Multiple studies used an ordinal clinical status severity scale as a primary outcome, ranging from meeting discharge criteria (lowest severity), to requiring hospitalization with supplemental oxygen (moderate severity), to death (highest severity); an example of one of these scales is shown in Table S3 in the Online Supplementary Document. The “standard of care” treatments provided to control groups were notably inconsistent, with most control groups having received treatment according to the national or hospital guidelines for standard of care at the time of the study period.

Table 2.  Summary of findings on COVID-19 (n = 34 studies)

ARDS – acute respiratory distress syndrome, BID – twice daily, CI – confidence intervals, CRP – C reactive protein, CT – computed tomography, HCQ – hydroxychloroquine, HR – hazard ratio, ICU – intensive care unit, IFN – interferon, IQR – interquartile range, OR- odds ratio, IV – intravenous, LOS – length of stay, LPV/r – lopinavir/ritonavir, N – number of participants, NAC – N-acetylcysteine, P:F – Pao2:FiO2, PO – per oral; QTc – corrected QT interval; rhG-CSF – recombinant human granulocyte colony stimulating factor, RR – respiratory rate, RoB – risk of bias, SpO2 – oxygen saturation, WBC – white blood cells


Two studies evaluated the use of antibiotics alone; both were RCTs evaluating azithromycin for hospitalized COVID-19 patients and found no difference in mortality with the addition of azithromycin to standard of care. In Brazil, Furtado et al. [23] found no difference in clinical status (odds ratio (OR) = 1.36, 95% confidence interval (CI) = 0.94, 1.97) or hospital length of stay (LOS) (26 vs 18 days; P = 0.064) was found among the treatment groups, however in Iran, Sekhavati et al. [24] found decreased hospital LOS (4.61 days vs 5.96 days; P = 0.02), and slightly higher SpO2 (93.95% vs92.40%; P = 0.030) was found in the azithromycin group. Notably, the standard of care in Brazil included hydroxychloroquine (HCQ) daily while in Iran included lopinavir/ritonavir (LPV/r) and HCQ.


HCQ and chloroquine (CQ) were evaluated in four studies, including three RCTs. Among the RCTs, Abd-Elsalam et al. [25] and Cavalcanti et al. [27] found no benefit for HCQ on clinical status, need for MV, or mortality, while Borba et al. [26] found potential harm with higher risk of death (39% vs 15%; OR = 3.6, 95% CI = 1.2 to 10.6) among those treated with high-dose vs low-dose CQ. Both RCTs in Brazil found greater QTc prolongation with CQ and HCQ [26,27]. One retrospective cohort in China by Yu et al. [28] found lower mortality among HCQ treated patients (18.8% HCQ vs 47.4% non-HCQ; P < 0.001) but no difference in hospital LOS and with a serious risk of bias.


Three RCTs and two retrospective cohort studies evaluated antivirals. Among RCTs, Abbaspour Kasgari et al. [29] evaluated sofosbuvir/daclatasvir with ribavirin vs LPV/r with or without ribavirin, Sadeghi et al. [32] evaluated sofosbuvir/daclatasvir, and Y Wang et al. [33] evaluated remdesivir; none of these studies found any benefit for the interventions studied on hospital LOS, mortality, or clinical status. In a retrospective cohort from Thailand, Prasithsirikul et al. [31] found no benefit for adjunctive favipiravir on hospital LOS (8 vs 10 days; P = 0.86) or time to viral clearance although this study had serious risk of bias due to multiple non-standardized therapeutics used in the comparator groups. Another retrospective cohort by Deng et al. [30] found greater viral clearance (75% vs 35%; P < 0.05) at seven days with use of umifenovir in addition to LPV/r vs LPV/r alone, although this study was seriously limited by small sample size (n = 16). Another retrospective cohort study in Iran by Vahedi et al. evaluated two different combinations of antibiotic plus antiviral plus other therapeutics found decreased hospital LOS (6.97 vs 9.93 days; P = 0.001) for azithromycin, prednisolone, naproxen, LPV/r vs meropenem, levofloxacin, vancomycin, HCQ and oseltamivir [34].

Convalescent plasma

Two RCTs by Agarwal et al. [35] and Li et al. [36] evaluated convalescent plasma; both found no benefit on clinical status or mortality, although Li et al. found possible benefit in clinical improvement in those with severe but non-critical disease with 91.3% vs 68.2% having clinical improvement at 28 days (HR = 2.15; 95% CI = 1.07 to 4.32).


Seven studies evaluated corticosteroids, including three RCTs and four retrospective cohort studies. Among RCTs, in Brazil, Jeronimo et al. [38] and Tomazini et al. [41] found no effect of steroids on mortality; however, Jeronimo et al. found decreased mortality in a sub-group analysis among patients over 60 years (46.6% vs 61.9%, P = 0.039) and Tomazini et al. found a higher number of ventilator-free days (6.6 vs 4.0 days; P = 0.04) among steroid-treated patients requiring mechanical ventilation (MV). In an RCT from Iran, Edalatifard et al. [37] found that among patients with elevated CRP and IL-6, steroids reduced hospital LOS (11.6 vs 17.6 days; P = 0.006), time to clinical improvement (11.8 vs 16.4 days; P = 0.011) and mortality (5.9% vs 42.9%; P < 0.001). In retrospective studies however, three studies in China found no difference in hospital LOS or mortality [39,42,43]. In Pakistan, Rana et al. [40] found improved Pao2:FiO2 (170 vs 118; P < 0.001) for dexamethasone vs methylprednisolone, however no other clinically relevant outcomes were evaluated.


Six studies evaluated immunomodulators including recombinant granulocyte colony-stimulating factor (rG-CSF), nasal interferon-kappa (IFN-k) with Trefoil factor 2 (TFF2), intravenous immunoglobulin (IVIG), IFN-a2b, IFN-b, and tocilizumab. One RCT by Cheng et al. [44] found no effect for rG-CSF on time to clinical improvement, however, lower 21-day mortality (secondary outcome) was seen in the treatment group (2% vs 10%), although was limited by small sample size. Among the two other RCTs, Gharebaghi et al. [46] found benefit for IVIG on in-hospital mortality (20% vs 48.3%; P = 0.022) and Rahmani et al. [48] found benefit for subcutaneous IFN-1b on time to clinical improvement (9 vs 11 days; P = 0.002) and hospital LOS (11 vs 13 days; P = 0.05), although no difference in 28-day mortality. A non-randomized trial by Fu et al. [45] found benefit for TFF-2 with IFN-k on hospital LOS (12 vs 15 days; P < 0.001), time to chest CT improvement (5 vs 8.5 days; P < 0.05) and time to viral clearance (6 vs 9.5 days; P < 0.05). Among retrospective studies, one cohort study by Zheng et al. found improvements in laboratory markers (WBC, CRP) with tocilizumab, but also longer hospital LOS (27.5 vs 16.4 days; P < 0.001) and higher mortality (9.8% vs 1.1%; P = 0.018), although patients who received tocilizumab were more likely to have severe/critical illness [49]. One case-control study by Hao et al. found no difference in viral clearance, need for MV or hospital LOS for IFN-a2b nasal spray [47].

Nutrients and minerals

One RCT by Abd-Elsalam et al. [50] evaluated the use of zinc with HCQ vs HCQ alone and found no difference in hospital LOS (13.5 vs 14 days; P = 0.553), clinical status (79.2% vs 77.9%, P = 0.969), or mortality (94.8% vs 94.7%; P = 0.986).

Respiratory tract agents

One RCT by de Alencar et al. evaluated the mucolytic agent N-acetylcysteine and found no difference in need for MV (20.6% vs 23.8%; P = 0.641), need for ICU admission (43% vs 47%; P = 0.557), or mortality (14% both groups; P = 0.940) [52]. Another RCT by Ansarin et al. assessed the mucolytic agent bromhexine and found decreased need for ICU admission (5.1% vs 28.2%; P = 0.006), need for MV (2.6% vs 23.1%; P = 0.007) and mortality (0% vs 12.8%; P = 0.027) [51].

Traditional Chinese medicine

TCM was evaluated in three RCTs and one retrospective cohort study, all from China. One RCT by Xiong et al. [56] evaluated Xuanfei Baidu, Wang et al. [54] evaluated Keguan Huo, and Xiao et al. [55] compared Huo Xiang Zhengqi plus Lianhua Qingwen vs Lianhua Qingwen alone vs standard of care alone (oseltamivir, arbidol, ribavirin). All RCTs included “Western medicine” in standard of care, although regimens were highly variable. Additionally, the primary outcomes varied substantially, and included time to symptom resolution, acute respiratory distress syndrome (ARDS) development, viral clearance, chest imaging improvement and progression to severe disease. Benefit was seen for Xuanfei Baidu with higher rate of symptom resolution at seven days (resolution of fever 90% vs 72.3%; P = 0.043) and for Keguan with decreased development of ARDS (4.2% vs 26.1%; P = 0.048) although this study had high concern for bias [54,56] The combination of Huo Xiang Zhengqi with Lianhua Qingwen had no benefit on progression to severe disease vs Lianhua Qingwen alone or standard of care (8.6% vs 1.6% vs 11.1%; P = 0.089). One retrospective study by Liu et al. found benefit for Jinhua Qinggan on time to viral clearance (7 vs10 days; P = 0.01) and time to chest imaging improvement (8 vs 10 days; P = 0.02) although the study had serious risk of bias [53]

Community-acquired pneumonia and lower respiratory tract infections

There were 15 articles on CAP and LRTIs, including 11 RCTs and four observational studies (Table 3).

Table 3.  Summary of findings on community-acquired pneumonia and lower respiratory tract infections (n = 15 studies)

BID – twice daily, CI – confidence intervals, CT – computed tomography, ICU – intensive care unit, IV – intravenous, LOS – length of stay, mg – milligram, N – number of participants, PO – per oral, RoB – risk of bias, RR – respiratory rate, SpO2 – oxygen saturation, IRR – incidence rate ratio


Nine of the 15 studies evaluated antibiotic regimens. Four of the eight RCTs evaluating antibiotics found no difference in clinical efficacy when comparing the following antibiotic regimens: gatifloxacin vs ceftriaxone (92% and 88% cure rate; P-value not reported), biapenem vs meropenem (94.7% vs 93.75% clinical efficacy; P-value not reported), levofloxacin five day vs seven day course (cure rate 56% vs 56.8%; difference = -0.8; 95% CI = -13.9 to 12.3) and levofloxacin vs ceftriaxone with azithromycin (hospital LOS 3.3 vs 3.4; P = 0.15) [59,61,63,64]. Abengowe et al. [57] found higher cure rates (68.2% vs 36.5%; P < 0.01) with TMP-SMX over tetracycline in Nigeria, and Chaudhary et al. [58] found benefit for ceftazidime-tobramycin over ceftriaxone in India (88.4% vs 61.2%; P-value not reported), although with high risk of bias. Tieying et al. [62] found that clinical cure at seven days was greater for moxifloxacin over levofloxacin/metronidazole (76.7% vs 51.7%; P = 0.045) among patients with CAP with aspiration risk factors at seven days, although no difference at the end of the treatment period at 14 days (83.3% vs 71.8%; P = 0.233). In a five-country non-inferiority study in Asia, Zhong et al. [65] found higher clinical cure rate for ceftaroline vs ceftriaxone (84% vs 74%, 95% CI = 2.8 to 17.1). Two retrospective cohort studies found no difference in hospital LOS or mortality between national antibiotic guideline-concordant or guideline-discordant groups, although in Brazil, Silveira et al. found a trend toward shorter LOS (12 vs 16 days; P = 0.066) in guideline-concordant patients and in multivariable analysis, a lower risk of 30-day mortality (RR = 0.85, 95% CI = 0.76 to 0.96) in guideline-concordant patients [68,69]. One prospective cohort study in Malaysia by Loh et al. [60] found no benefit to addition of a macrolide to broad-spectrum antibiotics on hospital mortality (17.6% vs 18.2%; P = 0.966) or LOS (7.0 vs 6.0 days, P = 0.401).

Other interventions

One RCT by Song et al. evaluated the TCM treatment XueBiJing, hypothesized to have anti-inflammatory and immunomodulatory effects, and found improvements in pneumonia severity index (60.8% vs 46.3%;  P < 0.001and lower 28-day mortality (15.87% XueBiJing vs 24.63%; P = 0.006) [70]. One RCT by Sharafi et al. evaluated the use of adjunctive zinc in older patients >50 years with CAP and found no benefit for use of zinc on hospital LOS [71]. Nafae et al. evaluating corticosteroids in an RCT in Egypt which showed reduced mortality (6.7% vs 31.6%; P < 0.05), and reduced hospital LOS (9.3 vs 16.5 days; P < 0.05) among patients treated with adjuvant hydrocortisone [67]. However, in a retrospective cohort study in Pakistan, Iqbal et al. found no effect of steroids on hospital mortality (absolute odds ratio (aOR) = 0.85, 95% CI = 0.39 to 1.88) and found the steroid group had longer hospital LOS (incidence rate ratio (IRR) = 1.51, 95% CI = 1.37 to 1.66) although was limited by lack of data on timing of steroid administration [66].

Influenza (including H1N1 and H7N9)

There were seven studies on influenza: six evaluated neuraminidase inhibitors (NAIs) and one evaluated corticosteroids (Table 4). Among the six studies on NAIs, two were RCTs and four were retrospective cohort studies; five were conducted in China. Among RCTs, Li et al. [75] found shorter duration until symptom resolution with oseltamivir vs placebo; however, the magnitude of effect varied with one study showing a reduction in duration of symptoms of less than five hours (91.6 vs 95 hours; P = 0.0466) while Lin et al. [76] found a reduction of 64 hours (110 vs 174 hours; P = 0.0479). Three of the retrospective cohort studies evaluating NAIs found benefit for oseltamivir. Chen et al. [73] found a decreased need for MV (OR = 0.325, 95% CI = 0.123 to 0.858) and mortality (OR = 0.416, 95% CI = 0.184 to 0.944) with early initiation (within two days of symptom onset) of oseltamivir in Influenza B, and also similarly found decreased need for MV (OR = 0.511, 95% CI = 0.312 to 0.835) and mortality (OR = 0.533, 95% CI = 0.210 to 0.807) with early oseltamivir treatment in Influenza A [72]. Lenzi et al. [74] also found decreased mortality (OR = 0.031, 95% CI = 0.015 to 0.065) with oseltamivir treatment. In a retrospective cohort study, Zhang et al. evaluated peramivir but found no benefit for the addition of peramivir to oseltamivir on development of time to viral clearance (7.0 vs 6.5 days; P = 0.67), development of ARDS (77.8% vs 63.9%; P = 0.30) or mortality (43.6% vs 25.6%; P = 0.11) [77]. Cao et al. [78] performed a propensity score-matched case-control study and found that high-dose adjuvant steroid use was associated with higher mortality at 30 days (adjusted hazard ratio (aHR) = 3.05, 95% CI = 1.28 to 7.25) in patients with H7N9 influenza while no association was seen with low or moderate doses.

Table 4.  Summary of findings on influenza (including H1N1 and H7N9 (n = 7 studies))

aHR – adjusted hazard ratio, ARDS – acute respiratory distress syndrome, BID – twice daily, CI – confidence interval, HR – heart rate, ICU – intensive care unit, IV – intravenous, LOS – length of stay, NAI – neuraminidase inhibitor, N – number of participants, OR – odds ratio, PO – per oral, RoB – risk of bias, RR – respiratory rate, ICU – intensive care unit

Severe acute respiratory infection

Only one study used the SARI definition as inclusion criteria, a double-blind RCT in Mexico by Gamiño-Arroyo et al. [79] which found no difference in hospital LOS (6.5 vs 7.0 days; P = 0.56) or viral clearance at day 3 (21.5% vs 21.3%; P = 0.98) in patients treated with the antiparasitic nitazoxanide (shown to have in vitro antiviral activity) (Table 5).

Table 5.  Summary of findings on severe acute respiratory infections and severe acute respiratory syndrome (n = 2 studies)

BID – twice daily, IQR – interquartile range, CI – confidence interval, LOS – length of stay, NAI – neuraminidase inhibitor, N – number of participants, OR – odds ratio, RCT – randomized controlled trial, RoB – risk of bias, SARI – severe acute respiratory infection, SARS – severe acute respiratory syndrome

Severe acute respiratory syndrome

One retrospective cohort study in China by Chen et al. [80] found no difference in mortality or hospital LOS between patients with SARS who received corticosteroids and those who did not; however, among patients with critical illness, there was lower mortality (OR = 0.083, 95% CI = 0.007 to 0.956) and shorter hospital LOS (OR = 1.743, 95% CI = 1.025 to 2.964) with corticosteroid use although the exact steroid dosages and timing of administration were not described (Table 5).


This systematic review broadly evaluated the impact of acute and emergency care interventions on clinical outcomes of adolescents and adults meeting the SARI case definition in LMICs. We found a critical lack of evidence exists for best practices in the management of undifferentiated SARIs across resource-limited settings, despite the overall low- to moderate-quality evidence for the benefit of early administration of certain pharmacologic interventions (eg, antivirals, antibiotics, immunomodulators) on the outcomes of patients with specific aetiologies of SARI (eg, influenza, COVID-19). None of the included studies evaluated non-pharmacologic interventions or were conducted in LICs.

One of this review’s strengths was the use of the SARI definition as an inclusion criterion, mimicking the real-world nature of evaluating patients with initially undifferentiated respiratory infections and avoiding reliance on laboratory diagnostics or suspicion of a specific pathogen as inclusion criteria. Multiple respiratory viruses such as influenza, SARS, and SARS-CoV-2, as well as (presumably) bacterial causes of pneumonia (few studies included information on confirmatory microbiologic diagnoses for studies on pneumonia) were included by these criteria. This also ensured that all relevant studies on SARIs would be included in the review, even if the SARI term itself was not used (eg, if the study was published before the SARI definition was created in 2011). The greatest variety of interventions were found among COVID-19 studies, while interventions for other SARIs were largely limited to antibiotics and antivirals. Not surprisingly, this review was dominated by the recent surge of publications related to COVID-19, as noted in multiple other fields, with only 21 of the 58 included articles (36%) published prior to 2020 [81,82].

All but one study required preliminary or confirmatory diagnosis of the likely aetiologic pathogen(s) causing SARI, usually via laboratory testing and/or radiologic imaging. While this helped ensure homogeneity of the study population relevant for targeted therapeutics such as antivirals or antibiotics, aetiologies of SARIs are often unknown to clinicians during the early period of care due to limited diagnostic capacities in LMICs. This review has highlighted the need for research on SARIs in LMICs using clinically based inclusion criteria, and increased focus on undifferentiated patient populations, prior to or without etiologic diagnostic test result requirements. Three major disease processes dominated the review – COVID-19, influenza, and CAP. Notably, all the interventions studied were pharmacologic in nature.

Studies on viral respiratory diseases were largely focused on the use of antivirals, while those on CAP focused on comparisons of antibiotic regimens. Most studies on CAP showed a non-inferiority of the studied antibiotics compared to control groups and mixed evidence on the utility of steroids in CAP. The most consistent, highest-quality evidence was on the benefit of NAIs for influenza treatment. NAIs were found to reduce symptom duration, clinical severity, and decreased patients’ risk of needing MV and risk of death. Despite the relative strength of these findings, substantial debate exists regarding the effectiveness and safety of NAIs for influenza and the appropriateness of stockpiling these drugs for use in influenza pandemics [83,84]. Much of this debate has been based on several large systematic reviews and meta-analyses (including one Cochrane collaboration report) which included data from unpublished manufacturer-funded trials [8587]. These reviews found that, despite a significant but short (approximately half a day) reduction in symptom duration, there remains a lack of credible data on the effect of NAIs on the outcomes of greatest clinical interest, such as reducing severe complications of influenza, risk of hospitalization, or death [8587]. Additionally, given that five of the six included studies on NAIs in this review were conducted in a single upper-middle income country (China), further research on the utility of NAIs in other LMICs, and focusing on outcomes of hospitalization and death, are greatly needed.

Among studies on COVID-19, little to no benefit was seen for most of the proposed therapeutics. Overall, the studies show a lack of benefit for azithromycin, HCQ and CQ, and convalescent plasma; mixed results were found with certain antivirals, corticosteroids and immunomodulators, with some studies noting differential effects among certain sub-groups (eg, corticosteroids for severe illness). However, the lack of standardization of a standard-of-care for control groups across countries or within the same country at different time points of the pandemic makes the extrapolation of these findings to other populations or contexts extremely difficult. Internationally standardized and evidence-based guidelines for the care of COVID-19 patients enrolled in research studies appropriate for LMIC settings (where access to supportive care such as supplemental oxygen may not be guaranteed) are needed. Importantly, given the volume of publications since the conclusion of this review’s search, an updated review of the literature on acute and emergency care interventions for COVID-19 in LMICs is warranted and is planned by this study team. Additionally, as this study was conducted before the roll-out of COVID-19 vaccines, the magnitude of effect of the interventions studied may differ among vaccinated individuals.

Five of the included studies evaluated the impact of TCM on SARIs, all conducted in China. All but one study found benefit of TCM on outcomes; however, the primary outcomes were highly variable, with most focusing on metrics such as symptom resolution or chest imaging improvements and only one including mortality as an outcome. Given the cultural context of TCM and limited use outside of East Asia, as well as the concomitant use of TCM alongside “Western medicine” in these studies, it is unclear how TCM interventions would be applied practically in other settings [88]

Unfortunately, no studies evaluated other intervention types such as oxygen administration strategies, ventilation strategies, or other supportive care strategies. While it is possible that this search strategy missed some studies, we believe this is not the case, as numerous non-pharmacologic interventions identified in this group’s concurrent paediatric-focused review (to be published separately) used the same search strategy; in the paediatric-focused review, more than 20% of the included articles evaluated respiratory support or physiotherapy interventions. Additionally, no additional relevant studies were found during cross-checking of reference lists of the articles. Lastly, we know that there is a lack of studies evaluating non-pharmacologic interventions for SARI in LMICs.

This study’s findings are mostly consistent with existing guidelines on the management of patients with respiratory infections in LMICs, which have focused primarily on pharmacologic (antibiotic and antiviral) treatments[89,90]. Resources such as WHO’s Clinical Care for SARI toolkit have been a great asset in the rapidly changing context of COVID-19 with inclusion of a living guideline on COVID-19 therapeutics and specific ventilation strategies for SARI, although guidance remains largely extrapolated from research conducted in high-resource settings rather than LMICs [6]. Additionally, recent guidelines created by and for those working primarily in resource-limited emergency care settings have increased emphasis on the care of undifferentiated severe respiratory conditions and the provision of context-appropriate supportive care, with tailored recommendations corresponding to different levels of resource availability [91,92]. While these developments are encouraging, incorporation of high-quality evidence obtained from LMICs into guidelines for best practices in the early care of patients with SARIs is urgently needed. One outcome of the COVID-19 pandemic may be the increased global attention toward respiratory support and non-pharmacologic interventions on altering the course of SARIs. This recognition of its importance may hopefully translate to increased resources and infrastructure needed to support emergency and critical resources in LMICs, such as enhanced systems of oxygen delivery.

This review has several important limitations. Early in the development of this review, the study team faced challenges in defining the inclusion criteria in several respects. First, as the SARI definition includes “requires hospitalization,” studies in populations with few hospital-level facilities available may have been excluded, skewing study findings towards places with greater health care resources. Another challenge was in determining what interventions constituted “emergency care”. Given the scope of emergency care may not be clearly defined in many LMICs, the broad definition of “emergent and early interventions” led to a wide scope of interventions being included, such as those that may not clearly represent emergency care in which medication started within the first 24 hours of care. Additionally, few studies explicitly reported on the exact timing of interventions (eg, within the first few hours vs anytime during the first day of admission) making assessment of what counted as emergency care difficult. The authors opted to err on the side of caution (ie, increased inclusivity) where uncertainty existed and therefore some interventions may not strictly be considered emergency care in all contexts. As timing of interventions may greatly impact the trajectory of disease progression, future research on early and emergency care of patients should report these key metrics in publications. Additionally, some studies’ primary outcomes focused on metrics (such as non-inferiority) which may be less relevant to emergency care clinicians. Lastly, the broad nature of the conditions studied using the SARI definition, interventions, and outcomes made meta-analysis including pooling effect estimates unfeasible, as mentioned previously.

Since all LMICs were included in this review, the applicability of certain interventions, such as convalescent plasma (which require special blood bank services) or highly costly immunomodulators, to lower resourced settings are likely very limited. Given the heterogeneity in resources available in countries classified as upper-middle income vs low- or lower-middle incomes, reviews focused broadly on LMICs should consider classifying findings according to resource availability. A glaring gap identified in this review was the lack of any included studies conducted in LICs. The reason for the lack of data from LICs is unclear, but may be due to lower research capacity or funding for interventional trials, lower SARI surveillance capacity or a lower burden of epidemic-potential SARIs. It is also possible that adult-focused research has been of lesser priority in LICs, given more than 12% of articles in the concurrent paediatric focused analysis were conducted in LICs It is crucial that patients in LICs have equal opportunities for participation in research trials for SARI therapeutics and interventions, especially in the context of COVID-19. Lastly, studies on recent SARI outbreaks that primarily affected high-income countries (eg, MERS and SARS) were not included.


Despite a significant increase in research on the treatment of SARI since the start of the COVID-19 pandemic, few interventions for SARI in LMICs had high quality evidence for benefit on clinical outcomes. NAIs for influenza had the strongest evidence for decreasing symptom duration and disease severity although research in more diverse populations is needed. Further research evaluating non-pharmacologic interventions, immunomodulators, corticosteroids, and including emergency care-relevant metrics for patients with SARIs in low-resource settings in LMICs are greatly needed.

Additional material:

Online Supplementary Document


We thank Kelsey Sawyer of the Brown University Library for her assistance with development of the search strategies and retrieval. We thank the Global Emergency Medicine Literature Review (GEMLR) group for its support and dedication to this research.

Data availability: Data are available for free on reasonable request from the corresponding author.

[1] Funding: None.

[2] Authorship contributions: All authors were involved in conceptualizing and designing the study. SCG and PR developed the search strategy and SCG developed the data extraction forms. SCG, PR, CB, GO, and MS conducted the study screenings and data extraction. SCG led the data analysis and manuscript writing with support from PR, CB, GO, MS, SK, IT, and TB. SK, IT, TB were responsible for oversight of the study, methodological advice, and review and editing of the manuscript.

[3] Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.


[1] World Health Organization. The top 10 causes of death. [Accessed: 2021 Dec 9]. Available:

[2] C Troeger, B Blacker, IA Khalil, PC Rao, J Cao, and SRM Zimsen. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18:1191-210. 10.1016/S1473-3099(18)30310-4. [PMID:30243584]

[3] Y Sakr, R Ferrer, K Reinhart, R Beale, A Rhodes, and R Moreno. The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study. Intensive Care Med. 2016;42:817-28. DOI: 10.1007/s00134-015-4206-2. [PMID:26880091]

[4] . Using research to prepare for outbreaks of severe acute respiratory infection. BMJ Glob Health. 2019;4:e001061. [PMID:30899557]

[5] J Fitzner, S Qasmieh, AW Mounts, B Alexander, T Besselaar, and S Briand. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bull World Health Organ. 2018;96:122-8. DOI: 10.2471/BLT.17.194514. [PMID:29403115]

[6] World Health Organization. Clinical care of severe acute respiratory infections – Tool kit [Internet]. 2022 Available: Accessed: 2022 Apr 7.

[7] WA Fischer, M Gong, S Bhagwanjee, and J Sevransky. Global burden of Influenza: Contributions from Resource Limited and Low-Income Settings. Glob Heart. 2014;9:325-36. DOI: 10.1016/j.gheart.2014.08.004

[8] J Li, CL Song, T Wang, YL Ye, JR Du, and SH Li. Etiological and epidemiological characteristics of severe acute respiratory infection caused by multiple viruses and Mycoplasma pneumoniae in adult patients in Jinshan, Shanghai: A pilot hospital-based surveillance study. PLoS One. 2021;16:e0248750. 10.1371/journal.pone.0248750. [PMID:33750952]

[9] Z Zhu, X Lian, X Su, W Wu, GA Marraro, and Y Zeng. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020;21:224 DOI: 10.1186/s12931-020-01479-w. [PMID:32854739]

[10] YH Le, KC Nguyen, KK Coleman, TT Nguyen, ST Than, and HH Phan. Virus detections among patients with severe acute respiratory illness, Northern Vietnam. PLoS One. 2020;15:e0233117. 10.1371/journal.pone.0233117. [PMID:32396550]

[11] HJ Schünemann, J Khabsa, K Solo, AM Khamis, R Brignardello-Petersen, and A El-Harakeh. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19: a living systematic review of multiple streams of evidence. Ann Intern Med. 2020;173:204-16. DOI: 10.7326/M20-2306. [PMID:32442035]

[12] RAC Siemieniuk, JJ Bartoszko, L Ge, D Zeraatkar, A Izcovich, and E Kum. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980 DOI: 10.1136/bmj.m2980. [PMID:32732190]

[13] D Moher, A Liberati, J Tetzlaff, and DG Altman. Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9. DOI: 10.7326/0003-4819-151-4-200908180-00135. [PMID:19622511]

[14] AE Juliana, MJ Tang, L Kemps, AC Noort, S Hermelijn, and FB Plötz. Viral causes of severe acute respiratory infection in hospitalized children and association with outcomes: A two-year prospective surveillance study in Suriname. PLoS One. 2021;16:e0247000. 10.1371/journal.pone.0247000. [PMID:33606795]

[15] NH Razanajatovo, J Guillebaud, A Harimanana, S Rajatonirina, EH Ratsima, and ZZ Andrianirina. Epidemiology of severe acute respiratory infections from hospital-based surveillance in Madagascar, November 2010 to July 2013. PLoS One. 2018;13:e0205124. 10.1371/journal.pone.0205124. [PMID:30462659]

[16] CY Chang, S Abujaber, TA Reynolds, CA Camargo, and Z Obermeyer. Burden of emergency conditions and emergency care usage: new estimates from 40 countries. Emerg Med J. 2016;33:794-800. DOI: 10.1136/emermed-2016-205709. [PMID:27334758]

[17] AP Steptoe, B Corel, AF Sullivan, and CA Camargo. Characterizing emergency departments to improve understanding of emergency care systems. Int J Emerg Med. 2011;4:42 10.1186/1865-1380-4-42. [PMID:21756328]

[18] The World Bank. World Bank Country and Lending Groups – World Bank Data Help Desk Available: Accessed: 2022 Feb 11.

[19] World Health Organization. Adolescent health [Internet]. [Accessed 2022 Feb 11]. Available:

[20] JAC Sterne, J Savović, MJ Page, RG Elbers, NS Blencowe, and I Boutron. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898 10.1136/bmj.l4898. [PMID:31462531]

[21] JA Sterne, MA Hernán, BC Reeves, J Savović, ND Berkman, and M Viswanathan. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919 10.1136/bmj.i4919. [PMID:27733354]

[22] Medicare Model Guidelines USP. v6.0 & v5.0 | USP [Internet]. [Accessed 2022 Feb 12]. Available:

[23] RHM Furtado, O Berwanger, HA Fonseca, TD Correa, LR Ferraz, and MG Lapa. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396:959-67. DOI: 10.1016/S0140-6736(20)31862-6. [PMID:32896292]

[24] E Sekhavati, F Jafari, S Seyed Alinaghi, S Jamalimoghadamsiahkali, S Sadr, and M Tabarestani. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Int J Antimicrob Agents. 2020;56:106143. DOI: 10.1016/j.ijantimicag.2020.106143. [PMID:32853672]

[25] S Abd-Elsalam, ES Esmail, M Khalaf, EF Abdo, MA Medhat, and MS Abd El Ghafar. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. Am J Trop Med Hyg. 2020;103:1635-9. DOI: 10.4269/ajtmh.20-0873. [PMID:32828135]

[26] MGS Borba, FFA Val, VS Sampaio, MAA Alexandre, GC Melo, and M Brito. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e208857. DOI: 10.1001/jamanetworkopen.2020.8857. [PMID:32330277]

[27] AB Cavalcanti, FG Zampieri, RG Rosa, LCP Azevedo, VC Veiga, and A Avezum. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;383:2041-52. DOI: 10.1056/NEJMoa2019014. [PMID:32706953]

[28] B Yu, C Li, P Chen, N Zhou, L Wang, and J Li. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;63:1515-21. DOI: 10.1007/s11427-020-1732-2. [PMID:32418114]

[29] H Abbaspour Kasgari, S Moradi, AM Shabani, F Babamahmoodi, AR Davoudi Badabi, and L Davoudi. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75:3373-8. DOI: 10.1093/jac/dkaa332. [PMID:32812025]

[30] L Deng, C Li, Q Zeng, X Liu, X Li, and H Zhang. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020;81:e1-5. DOI: 10.1016/j.jinf.2020.03.002. [PMID:32171872]

[31] W Prasithsirikul, K Pongpirul, P Sakornsakolpat, C Burana, P Phutrakool, and WA Pongpirul. Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand. Asian Biomed. 2020;14:107-10. DOI: 10.1515/abm-2020-0016

[32] A Sadeghi, A Ali Asgari, A Norouzi, Z Kheiri, A Anushirvani, and M Montazeri. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75:3379-85. DOI: 10.1093/jac/dkaa334. [PMID:32812039]

[33] Y Wang, D Zhang, G Du, R Du, J Zhao, and Y Jin. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-78. DOI: 10.1016/S0140-6736(20)31022-9. [PMID:32423584]

[34] E Vahedi, M Ghanei, A Ghazvini, H Azadi, M Izadi, and Y Panahi. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. Daru. 2020;28:507-16. DOI: 10.1007/s40199-020-00353-w. [PMID:32562159]

[35] A Agarwal, A Mukherjee, G Kumar, P Chatterjee, T Bhatnagar, and P Malhotra. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939 DOI: 10.1136/bmj.m3939. [PMID:33093056]

[36] L Li, W Zhang, Y Hu, X Tong, S Zheng, and J Yang. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:460-70. DOI: 10.1001/jama.2020.10044. [PMID:32492084]

[37] M Edalatifard, M Akhtari, M Salehi, Z Naderi, A Jamshidi, and S Mostafaei. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56:62002808. DOI: 10.1183/13993003.02808-2020. [PMID:32943404]

[38] CMP Jeronimo, MEL Farias, FFA Val, VS Sampaio, MAA Alexandre, and GC Melo. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clin Infect Dis. 2020;

[39] Y Ma, H Zeng, Z Zhan, H Lu, Z Zeng, and C He. Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China. Front Pharmacol. 2020;11:PG-11981198 DOI: 10.3389/fphar.2020.01198. [PMID:32903363]

[40] MA Rana, M Hashmi, A Qayyum, R Pervaiz, M Saleem, and MF Munir. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients. Cureus. 2020;12:e10918. DOI: 10.7759/cureus.10918. [PMID:33194485]

[41] BM Tomazini, IS Maia, AB Cavalcanti, O Berwanger, RG Rosa, and VC Veiga. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324:1307-16. DOI: 10.1001/jama.2020.17021. [PMID:32876695]

[42] J Wu, J Huang, G Zhu, Y Liu, H Xiao, and Q Zhou. Systemic Corticosteroids and Mortality in Severe and Critical COVID-19 Patients in Wuhan, China. J Clin Endocrinol Metab. 2020;105:dgaa627. DOI: 10.1210/clinem/dgaa627. [PMID:32880390]

[43] L Zha, S Li, L Pan, B Tefsen, Y Li, and N French. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212:416-20. DOI: 10.5694/mja2.50577. [PMID:32266987]

[44] LL Cheng, WJ Guan, CY Duan, NF Zhang, CL Lei, and Y Hu. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181:171-8. [PMID:32910179]

[45] W Fu, Y Liu, L Liu, H Hu, X Cheng, and P Liu. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. EClinicalMedicine. 2020;27:PG-100547100547. DOI: 10.1016/j.eclinm.2020.100547. [PMID:32984784]

[46] N Gharebaghi, R Nejadrahim, SJ Mousavi, SR Sadat-Ebrahimi, and R Hajizadeh. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20:786 DOI: 10.1186/s12879-020-05507-4. [PMID:33087047]

[47] SR Hao, R Yan, SY Zhang, JS Lian, H Cai, and XL Zhang. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study. J Zhejiang Univ Sci B. 2020;21:628-36. DOI: 10.1631/jzus.B2000211. [PMID:32748578]

[48] H Rahmani, E Davoudi-Monfared, A Nourian, H Khalili, N Hajizadeh, and NZ Jalalabadi. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020;88:PG-106903106903. DOI: 10.1016/j.intimp.2020.106903. [PMID:32862111]

[49] KL Zheng, Y Xu, YF Guo, L Diao, XY Kong, and XJ Wan. Efficacy and safety of tocilizumab in COVID-19 patients. Aging (Albany NY). 2020;12:18878-88. DOI: 10.18632/aging.103988. [PMID:33031060]

[50] S Abd-Elsalam, S Soliman, ES Esmail, M Khalaf, EF Mostafa, and MA Medhat. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine? A Randomized, Multicenter Trial. Biol Trace Elem Res. 2021;199:103642-6. [PMID:33247380]

[51] K Ansarin, R Tolouian, M Ardalan, A Taghizadieh, M Varshochi, and S Teimouri. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. Bioimpacts. 2020;10:209-15. DOI: 10.34172/bi.2020.27. [PMID:32983936]

[52] JCG de Alencar, CL Moreira, AD Muller, CE Chaves, MA Fukuhara, and EA da Silva. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19. Clin Infect Dis. 2021;72:11e736-e741. [PMID:32964918]

[53] Liu Z, Li X, Gou C, Li L, Luo X, Zhang C, et al. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients. J Tradit Chin Med [Internet]. 2020;40(3 PG-467–472):467–72. –

[54] JB Wang, ZX Wang, J Jing, P Zhao, JH Dong, and YF Zhou. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial. Chin J Integr Med. 2020;26:648-55. DOI: 10.1007/s11655-020-3426-7. [PMID:32676976]

[55] M Xiao, J Tian, Y Zhou, X Xu, X Min, and Y Lv. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial. Pharmacol Res. 2020;161:PG-105126105126. DOI: 10.1016/j.phrs.2020.105126. [PMID:32781283]

[56] WZ Xiong, G Wang, J Du, and W Ai. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial. Integr Med Res. 2020;9:100489. DOI: 10.1016/j.imr.2020.100489. [PMID:32874913]

[57] CU Abengowe. Comparative trial of co-trimoxazole and tetracycline in the treatment of lower respiratory tract infection. Curr Med Res Opin. 1979;5:749-53. DOI: 10.1185/03007997909109008. [PMID:373988]

[58] M Chaudhary, SM Shrivastava, and R Sehgal. Evaluation of efficacy and safety of fixed dose combination of ceftazidime-tobramycin in comparison with ceftazidime in lower respiratory tract infections. Curr Clin Pharmacol. 2009;4:62-6. DOI: 10.2174/157488409787236119. [PMID:19149503]

[59] M Izadi, B Dadsetan, Z Najafi, S Jafari, E Mazaheri, and O Dadras. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients. Recent Pat Antiinfect Drug Discov. 2018;13:228-39. DOI: 10.2174/1574891X13666181024154526. [PMID:30360748]

[60] LC Loh, SY Quah, SK Khoo, P Vijayasingham, and T Thayaparan. Addition of macrolide in treating adult hospitalized community-acquired pneumonia. Respirology. 2005;10:371-7. DOI: 10.1111/j.1440-1843.2005.00704.x. [PMID:15955152]

[61] JS Mendonça, A Yamaguti, JC Corrêa, and R Badaró. Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia. Braz J Infect Dis. 2004;8:90-100. . InternetDOI: 10.1590/S1413-86702004000100006. [PMID:15286880]

[62] T Sun, SUN Li, W Rongmei, REN Xiaoping, SUI Dong-Jiang, and PU Chun. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Chin Med J (Engl). 2014;24:71201-5. [PMID:24709166]

[63] X Wang, X Zhang, Z Zong, R Yu, X Lv, and J Xin. Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial. Indian J Med Res. 2013;138:995-1002. [PMID:24521647]

[64] X Zhao, JF Wu, QY Xiu, C Wang, DP Zhang, and JA Huang. A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia. Diagn Microbiol Infect Dis. 2014;80:141-7. DOI: 10.1016/j.diagmicrobio.2013.11.008. [PMID:25130297]

[65] NS Zhong, T Sun, C Zhuo, G D’Souza, SH Lee, and NH Lan. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;15:161-71. DOI: 10.1016/S1473-3099(14)71018-7. [PMID:25539586]

[66] N Iqbal, M Irfan, F Siddiqui, V Arshad, and ABS Zuabairi. Effects of systemic steroids on patients with community-acquired pneumonia: Observational study from a tertiary care hospital of a developing country. Respir Investig. 2020;58:6495-501. DOI: 10.1016/j.resinv.2020.05.004. [PMID:32665194]

[67] Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Vol. 62. 2013. p. 439–45.

[68] P Annisa, G Syed Wasif, and SS Syed Azhar. Antibiotics management and outcome of therapy for patients with community-acquired pneumonia in Hospital Pulau Pinang, Malaysia. Int J Pharm Life Sci. 2014;5:3367-73.

[69] CD Silveira, CS Ferreira, and A Corrêa Rde. Adherence to guidelines and its impact on outcomes in patients hospitalized with community-acquired pneumonia at a university hospital. J Bras Pneumol. 2012;38:148-57. DOI: 10.1590/S1806-37132012000200002. [PMID:22576421]

[70] Y Song, C Yao, Y Yao, H Han, X Zhao, and K Yu. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. Crit Care Med. 2019;47:e735-43. DOI: 10.1097/CCM.0000000000003842. [PMID:31162191]

[71] S Sharafi and A Allami. Efficacy of zinc sulphate on in-hospital outcome of community-acquired pneumonia in people aged 50 years and over. Int J Tuberc Lung Dis. 2016;20:685-8. DOI: 10.5588/ijtld.15.0653. [PMID:27084825]

[72] L Chen, X Han, Y Li, C Zhang, and X Xing. Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study. Eur J Clin Microbiol Infect Dis. 2020;39:1231-8. DOI: 10.1007/s10096-020-03835-6. [PMID:32026193]

[73] L Chen, X Han, YL Li, C Zhang, and X Xing. The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study. BMC Infect Dis. 2020;20:628 DOI: 10.1186/s12879-020-05322-x. [PMID:32842994]

[74] Lenzi L, Grochocki MHC, Silva LR, Wiens A, Mello AM, Pontarolo R. Evaluation of the Effectiveness of Oseltamivir for the Treatment of 2009 Pandemic Influenza A (H1N1). 2012;(PG-). Available from:

[75] L Li, B Cai, M Wang, and Y Zhu. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin Med J (Engl). 2003;116:44-8. DOI: 10.3901/JME.2003.06.044. [PMID:12667386]

[76] JT Lin, XZ Yu, DJ Cui, XY Chen, JH Zhu, and YZ Wang. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin. 2006;22:75-82. DOI: 10.1185/030079906X80297. [PMID:16393433]

[77] Y Zhang, H Gao, W Liang, L Tang, Y Yang, and X Wu. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infect Dis. 2016;16:PG-7676 DOI: 10.1186/s12879-016-1383-8. [PMID:26864456]

[78] B Cao, H Gao, B Zhou, X Deng, C Hu, and C Deng. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. Crit Care Med. 2016;44:e318-28. DOI: 10.1097/CCM.0000000000001616. [PMID:26934144]

[79] AE Gamiño-Arroyo, ML Guerrero, S McCarthy, A Ramirez-Venegas, B Llamosas-Gallardo, and A Galindo-Fraga. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Clin Infect Dis. 2019;69:1903-11. DOI: 10.1093/cid/ciz100. [PMID:30753384]

[80] RC Chen, XP Tang, SY Tan, BL Liang, ZY Wan, and JQ Fang. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129:1441-52. DOI: 10.1378/chest.129.6.1441. [PMID:16778260]

[81] S Gianola, TS Jesus, S Bargeri, and G Castellini. Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic. PLoS One. 2020;15:e0240123. DOI: 10.1371/journal.pone.0240123. [PMID:33022014]

[82] SBS Kambhampati, R Vaishya, and A Vaish. Unprecedented surge in publications related to COVID-19 in the first three months of pandemic: A bibliometric analytic report. J Clin Orthop Trauma. 2020;11:Suppl 3S304 DOI: 10.1016/j.jcot.2020.04.030. [PMID:32405191]

[83] Robesyn E, Broberg E, Kramarz P. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza Review of recent systematic reviews and meta-analyses Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza-review of recent systematic reviews and meta-analyses. [Accessed 2022 Feb 11]; Available:

[84] The BMJ. Tamiflu campaign | The BMJ [Internet]. [Accessed 2022 Feb 11]. Available:

[85] T Jefferson, MA Jones, P Doshi, CB Del Mar, R Hama, and MJ Thompson. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;2014:CD008965. 10.1002/14651858.CD008965.pub4. [PMID:24718923]

[86] J Dobson, RJ Whitley, S Pocock, and AS Monto. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385:1729-37. DOI: 10.1016/S0140-6736(14)62449-1. [PMID:25640810]

[87] SG Muthuri, S Venkatesan, PR Myles, J Leonardi-Bee, TSA Al Khuwaitir, and A Al Mamun. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. lancet Lancet Respir Med. 2014;2:395-404. DOI: 10.1016/S2213-2600(14)70041-4. [PMID:24815805]

[88] L Ni, L Chen, X Huang, C Han, J Xu, and H Zhang. Combating COVID-19 with integrated traditional Chinese and Western medicine in China. Acta Pharm Sin B. 2020;10:1149-62. DOI: 10.1016/j.apsb.2020.06.009. [PMID:32834946]

[89] Médecins Sans Frontières. Clinical guidelines – Diagnosis and treatment manual [Internet]. Médecins Sans Frontières; 2021 [Accessed 2022 Mar 26]. Available:

[90] World Health Organization. IMAI district clinician manual: hospital care adolescents and adults: guidelines for the management of illnessess with limited-resources. 2012;

[91] Checkett K, Wallis L, Reynolds T, editors. AFEM Handbook of Acute and Emergency Care. Second. Cape Town, South Africa: Oxford University Press; 2018.

[92] World Health Organization. BASIC EMERGENCY CARE: approach to the acutely ill and injured. World Health Organization; 2018.

Correspondence to:
Stephanie C. Garbern, MD MPH
Department of Emergency Medicine
Alpert Medical School of Brown University
Providence, Rhode Island, USA
[email protected]